Altoprev

Altoprev is a brand name of lovastatin, approved by the FDA in the following formulation(s):

ALTOPREV (lovastatin - tablet, extended release; oral)

• 
  Manufacturer: ANDRX LABS LLC
  
  Approval date: June 26, 2002
  
  Strength(s): 20MG, 40MG, 60MG ^[RLD]

Has a generic version of Altoprev been approved?

No. There is currently no therapeutically equivalent version of Altoprev available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Altoprev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  HMG co-reductase inhibitor
  Patent 5,916,595
  Issued: June 29, 1999
  Inventor(s): Chen; Chih-Ming & Chou; Joseph & Wong; David
  Assignee(s): Andrx Pharmaceutials, Inc.
  A controlled release dosage formulation is described which is based on a combination of: (a) a compressed tablet core which contains an alkyl ester of a hydroxy substituted naphthalene derivative a pharmaceutically acceptable, water swellable polymer and an osmotic agent; and (b) an outer coating layer which completely covers the osmotic core and comprises a pH sensitive coating agent and a water insoluble polymer.
  
  Patent expiration dates:
  
  
  • December 12, 2017
    
  
  



• 
  Methods for decreasing beta amyloid protein
  Patent 6,080,778
  Issued: June 27, 2000
  Inventor(s): Yankner; Bruce A. & Nadeau; Philip
  Assignee(s): Children's Medical Center Corporation
  Blood cholesterol levels are correlated with production of amyloid .beta. protein (A.beta.), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A.beta., thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A.beta.. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels--especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.
  
  Patent expiration dates:
  
  
  • March 23, 2018
    
    ✓ 
    Patent use: METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
  
  



• 
  Once daily pharmaceutical tablet having a unitary core
  Patent 6,485,748
  Issued: November 26, 2002
  Inventor(s): Chih-Ming; Chen & Joseph C. H.; Chou
  Assignee(s): Andrx Pharmaceuticals, Inc.
  A controlled release tablet is disclosed which comprises: (a) a homogeneous compressed core which comprises: (i) a medicament which is very slightly soluble to practically insoluble in water at 25° C.; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of a: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) a pH dependent polymer such as an enteric coating polymer, the weight ratio of the pH dependent polymer to the water insoluble pharmaceutically acceptable polymer being 0.1:1 to 0.75:1. A controlled release tablet which comprises: (a) a medicament (a) a homogeneous compressed core which comprises: (i) a medicament; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) an enteric polymer.
  
  Patent expiration dates:
  
  
  • December 12, 2017
    
    ✓ 
    Drug product
  
  

See also...

• Altoprev Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Altoprev Consumer Information (Cerner Multum)
• Altoprev Advanced Consumer Information (Micromedex)
• Lovastatin Consumer Information (Wolters Kluwer)
• Lovastatin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Lovastatin Consumer Information (Cerner Multum)
• Lovastatin Advanced Consumer Information (Micromedex)
• Lovastatin AHFS DI Monographs (ASHP)